Anthropic Acquires Coefficient Bio for $400M — Its First Move Into Biological AI

Anthropic has quietly acquired Coefficient Bio, a stealth-mode AI startup focused on biological research, in a $400 million stock transaction—signaling the safety-focused AI lab's first serious expansion into life sciences. The deal was first reported by The Information and Eric Newcomer and has not yet been officially confirmed by Anthropic.

Coefficient Bio operated in stealth, which means its exact research focus remains opaque, but the acquisition price suggests Anthropic views biological AI as a significant strategic priority rather than a peripheral experiment. At $400 million in stock—not cash—Anthropic is betting that its own valuation growth will make the deal worthwhile for Coefficient Bio's team and investors.

The move follows a pattern visible across big AI labs: OpenAI has explored drug discovery partnerships, Google DeepMind has AlphaFold and AlphaProteo, and Microsoft has deep ties to biotech through its research division. Anthropic entering this space with a direct acquisition rather than a partnership suggests they want to move faster and own the research stack outright.

For the AI safety community, the acquisition raises interesting questions. Anthropic has built its brand on responsible AI development and constitutional AI methods. Applying those same principles to biological research—where the stakes around misuse are arguably even higher than in language AI—could either be a meaningful contribution to biosafety or a reputational risk if the work moves faster than the guardrails.

The timing is notable: Anthropic raised at an increasingly aggressive valuation just weeks ago, giving it the stock currency to make exactly this kind of move. Expect more acquisitions as the company looks to diversify beyond the API revenue it earns from Claude.